The Power to Protect


This vaccine is precision engineered, building on the trusted vaccination platform used to develop VAXXITEK® HVT+IBD, our research and manufacturing experts successfully designed a 3-in-1 vaccine that provides a strong immune foundation and optimizes protection against Marek’s disease (MD), infectious bursal disease (IBD), and infectious laryngotracheitis (ILT).


  • All the benefits of VAXXITEK® HVT+IBD now with the power of ILT protection

  • Simplified vaccination program: from field to hatchery

  • Developed by the trusted leader in IBD vector vaccine technology

  • Proven safety for your flock


Key Advantages

  • A single vaccination to protect against MD, IBD, and ILT1

  • Engineered using the same backbone as VAXXITEK® HVT+IBD

  • Demonstrated safety proven by clinical studies1

  • Immunogenic glycoprotein D ILT insert for optimal ILT protection

  • Protects efficiently against both classic and variant E IBDV1

  • Subcutaneous or in ovo administration of VAXXITEK® HVT+IBD+ILT provides reliable ILT protection1

  • Onset of immunity against MD shown from 5 days of age1



Features & Benefits

  • 3-in-1 vaccine: MD, IBD, and ILT protection

  • The strong immune foundation provided by the VAXXITEK® HVT+IBD backbone enables productivity, reduces antibiotic use, and supports return on investment2–8

  • Same VAXXITEK® technology platform ensures proper gene expression

  • Improved animal welfare through fewer vaccine applications1

  • Moving vaccination from field to hatchery reduces chick-handling stress

  • Reduced labor, time, and cost enable increased profitability

  • Safe and easy to use

Dosage & Administration

Packaged in 5 x 4000 dose ampules in frozen presentation











One Sheeter

VAXXITEK ILT One Sheet US-POU-0066-2020








  • Do not mix with other products, except as specified on the label

  • In case of human exposure, contact a physician

  • Administer only as recommended

  • Use entire contents when first opened

  • Do not vaccinate within 21 days before slaughter

  • Contains penicillin and streptomycin sulfate, which are added as bacteriostatic agents

  • Contains amphotericin B as a fungistatic agent

  • Inactivate unused contents before disposal

  • Safety comparable to existing HVT vector vaccines9

  • Proven to remain safe and stable; will not revert to virulence10


Safety Data Sheet


See How VAXXITEK® HVT-IBD+ILT protects poultry.



1Data on file at Boehringer Ingelheim.

2Morton DB. Vaccines and animal welfare. Rev Sci Tech. 2007;26:157-163.

3Lemiere S, Rojo F, Fernandez R, et al. Benefits of the herpesvirus of turkey vector vaccine of infectious bursal disease in control of immuno-depression in broilers and decrease of use of antibiotic medication. In: Proceedings from the XVIII Congress of the World Veterinary Poultry Association Congress; August 19-23, 2013; Nantes, France. Abstract.

4Hoelzer K, Bielke L, Blake DP, et all. Vaccines are alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions. Vet Res. 2018;49:70.

5Atienza JC, Nagera AJ, Martinez PO, et al. Evaluation of a herpesvirus of turkey vector vaccine including protection against infectious bursal and Marek’s diseases (VAXXITEK® HVT+IBD) under Philippines field conditions. In: Proceedings from the XXIII World’s Poultry Congress; June 29-July 4, 2008; Queensland, Australia.

6Rautenschlein S, Lemiere S, Simon B, Prandini F. A comparison of the effects of the humoral and cell-mediated immunity between an HVT-IBD vector vaccine and an IBDV-immune complex vaccine after in ovo vaccination of commercial broilers. In: Proceedings from the XVII Congress of the World Veterinary Poultry Association Congress; August 14-18, 2011; Cancun, Mexico. p830-843.

7Tang SF, He SJ, Li WM, Lemiere S. Field experience of vaccination in day-old broiler chickens with a herpesvirus turkey-infectious bursal disease (HVT-IBD) vector vaccine in different systems of chicken production across China. Poster presentation. In: Proceedings from the XVII Congress of the World Veterinary Poultry Association Congress; August 14-18, 2011; Cancun, Mexico, p920-926.

8Zhou X, Wang D, Xiong J, Zhang P, Li Y, She R. Protection of chickens, with or without maternal antibodies, against IBDV infectious by a recombinant IBDV-VP2 protein. Vaccine. 2010; 28:3990-3996.

9Data on file at Boehringer Ingelheim. 2017 Report 16-187.

10Data on file at Boehringer Ingelheim. 2017 R&D. Report number 17.0107.R.


VAXXITEK® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-POU-0057-2022